ArticleProceedings (Baylor University. Medical Center)2023
Recurrent malignant ovarian adenocarcinoma with central nervous system metastasis successfully treated with paclitaxel, carboplatin, capecitabine, and gemcitabine.
Article in Proceedings (Baylor University. Medical Center), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian carcinoma is a common malignancy with a grim prognosis and a high mortality rate. Here, we report a rare case of an Iranian woman with four episodes of recurrent metastatic ovarian carcinoma. She was initially diagnosed with stage IVa high-grade serous ovarian adenocarcinoma (HGSOC), treated with paclitaxel-carboplatin and capecitabine, followed by total abdominal hysterectomy and bilateral salpingo-oophorectomy. Two years later, she developed cerebellar metastasis and received whole-brain radiotherapy and paclitaxel-carboplatin. Eighteen months later, she had peritoneal metastasis and had sequential gemcitabine-carboplatin-paclitaxel. One year later, she had splenic metastasis, treated with splenectomy and adjuvant carboplatin and nano-albumin bond paclitaxel. The patient remains in remission until now, 11 months after completing the most recent regimen. This report emphasizes the potential to successfully use chemoradiotherapy with sequential courses of platinum-based agents in patients with recurrent metastatic HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.